Atopic dermatitis (AD) is one of the most common allergic diseases in children, with a
prevalence of more than 20% in high-income countries, which seriously affects the life …

Background Dupilumab is a monoclonal antibody that targets the interleukin (IL)-4 receptor
alpha subunit of the IL-4 and IL-13 receptor. This novel agent has received a license for the …

Dupilumab is a fully humanized monoclonal antibody that suppresses Th2‐mediated
inflammation by inhibiting signaling of interleukin‐4 and interleukin‐13 through the …

Atopic dermatitis (AD) is a chronic inflammatory skin disease principally characterized by
type 2 inflammation, skin barrier dysfunction, and itch (1). In developed countries, it affects …

Background: AD, a chronic inflammatory skin disease, can affect different parts of the body.
Dupilumab inhibits interleukin (IL)-4 and IL-13 signaling and is approved for treating multiple …

Dupilumab is the first human monoclonal antibody that treats atopic dermatitis (AD) by
blocking interleukin 4 (IL-4) and interleukin 13 (IL-13), which can suppress the Th2 …

Dear Editor: Dupilumab, a human monoclonal antibody against interleukin (IL)-4 receptor α,
is the first biologic therapy approved for the treatment of patients with moderate to severe …

Nephrotic syndrome (NS) tends to be more common in patients with history of allergies.
Atopic dermatitis (AD) is one of the most common allergic diseases in children. Dupilumab, a …

Background: Atopic dermatitis (AD) is a common skin disease that affects patients' quality of
life, especially in the pediatric population. Dupilumab has shown good efficacy and safety in …

Three of 20 patients (15%) reported mild gastrointestinal side-effects (gastric pain, nausea
or diarrhoea) not related to Clostridium difficile colitis. For two of three patients with …